Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer

NCT01347645 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
82
Enrollment
INDUSTRY
Sponsor class

Stopped The study was terminated by the Sponsor due to E7820 plus irinotecan being potentially inferior to FOLFIRI

Conditions

Interventions

Sponsor

Eisai Inc.

Collaborators